Preconception Ovarian Reserve and Placenta-mediated Pregnancy Complications Among Infertile Women

Overview

Journal Pregnancy Hypertens

Publisher Elsevier

Date 2022 Feb 8

PMID 35131729

Authors

Wendy Vitek

Jinhee Oh

Omar Mbowe

Sally W Thurston

Mindy S Christianson

Aaron K Styer

Alex J Polotsky

Michael P Diamond

Marcelle I Cedars

Affiliations

Soon will be listed here.

Abstract

Research Question: Are preconception ovarian reserve markers, such as Anti-Mullerian hormone and antral follicle count, associated with preeclampsia and placenta mediated pregnancy complications among women with unexplained infertility who conceive with superovulation?

Design: This is a secondary analysis of women with unexplained infertility who had a singleton live birth after enrollment in the Analysis of Multiple Intrauterine Gestations after Ovarian Stimulation (AMIGOS) trial that randomized couples to superovulation with letrozole, clomiphene, or gonadotropins with insemination for up to 4 cycles.

Results: Compared to controls (N = 156), women who developed preeclampsia (N = 17) had lower Anti-Mullerian hormone levels (2.24 ± 1.20 vs. 2.89 ± 2.32, p = 0.07) and lower antral follicle count (18 ± 7.67 vs. 21 ± 11.43, p = 0.16); though these differences were not statistically significant. There was no relationship between Anti-Mullerian hormone (OR: 1.00, 95% CI: 0.76-1.25) or antral follicle count (OR: 0.98, 95% CI 0.93-1.04) with preeclampsia and between Anti-Mullerian hormone (OR: 1.00, 95% CI: 0.83-1.17) and antral follicle count (OR: 1.00, 95% CI: 0.97-1.04) with placenta medicated pregnancy complications after adjusting for age, BMI and race.

Conclusions: Preconception ovarian reserve markers are not associated with preeclampsia and placenta mediated pregnancy complications among women with unexplained infertility who conceive with superovulation with insemination.

References

Birdir C, Fryze J, Vasiliadis H, Nicolaides K, Poon L . Maternal serum anti-Müllerian hormone at 11-13 weeks' gestation in the prediction of preeclampsia. J Matern Fetal Neonatal Med. 2014; 28(8):865-8. DOI: 10.3109/14767058.2014.937418. View

Woldringh G, Frunt M, Kremer J, Spaanderman M . Decreased ovarian reserve relates to pre-eclampsia in IVF/ICSI pregnancies. Hum Reprod. 2006; 21(11):2948-54. DOI: 10.1093/humrep/del155. View

Diamond M, Legro R, Coutifaris C, Alvero R, Robinson R, Casson P . Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. N Engl J Med. 2015; 373(13):1230-40. PMC: 4739644. DOI: 10.1056/NEJMoa1414827. View

Diamond M, Legro R, Coutifaris C, Alvero R, Robinson R, Casson P . Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics. Fertil Steril. 2015; 103(4):962-973.e4. PMC: 4529113. DOI: 10.1016/j.fertnstert.2014.12.130. View

von Versen-Hoynck F, Narasimhan P, Tierney E, Martinez N, Conrad K, Baker V . Absent or Excessive Corpus Luteum Number Is Associated With Altered Maternal Vascular Health in Early Pregnancy. Hypertension. 2019; 73(3):680-690. PMC: 6378337. DOI: 10.1161/HYPERTENSIONAHA.118.12046. View

Keegan D, Krey L, Chang H, Noyes N . Increased risk of pregnancy-induced hypertension in young recipients of donated oocytes. Fertil Steril. 2007; 87(4):776-81. DOI: 10.1016/j.fertnstert.2006.08.105. View

Tokmak A, Guney G, Aksoy R, Guzel A, Topcu H, Kececioglu T . May maternal anti-mullerian hormone levels predict adverse maternal and perinatal outcomes in preeclampsia?. J Matern Fetal Neonatal Med. 2014; 28(12):1451-6. DOI: 10.3109/14767058.2014.955007. View

Yarde F, Maas A, Franx A, Eijkemans M, Drost J, van Rijn B . Serum AMH levels in women with a history of preeclampsia suggest a role for vascular factors in ovarian aging. J Clin Endocrinol Metab. 2013; 99(2):579-86. DOI: 10.1210/jc.2013-2902. View

Romagnuolo I, Sticchi E, Attanasio M, Grifoni E, Cioni G, Cellai A . Searching for a common mechanism for placenta-mediated pregnancy complications and cardiovascular disease: role of lipoprotein(a). Fertil Steril. 2016; 105(5):1287-1293.e3. DOI: 10.1016/j.fertnstert.2016.01.014. View

10.

Brown M, Best K, Pearce M, Waugh J, Robson S, Bell R . Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2013; 28(1):1-19. DOI: 10.1007/s10654-013-9762-6. View

11.

LeFevre M . Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 161(11):819-26. DOI: 10.7326/M14-1884. View

12.

Shand A, Whitton K, Pasfield A, Nassar N, McShane M, Han X . Evaluation of anti-Mullerian hormone in the first trimester as a predictor for hypertensive disorders of pregnancy and other adverse pregnancy outcomes. Aust N Z J Obstet Gynaecol. 2014; 54(3):244-9. DOI: 10.1111/ajo.12183. View

13.

Quinn M, Kao C, Ahmad A, Haisenleder D, Santoro N, Eisenberg E . Age-stratified thresholds of anti-Müllerian hormone improve prediction of polycystic ovary syndrome over a population-based threshold. Clin Endocrinol (Oxf). 2017; 87(6):733-740. DOI: 10.1111/cen.13415. View

14.

Singh B, Reschke L, Segars J, Baker V . Frozen-thawed embryo transfer: the potential importance of the corpus luteum in preventing obstetrical complications. Fertil Steril. 2020; 113(2):252-257. PMC: 7380557. DOI: 10.1016/j.fertnstert.2019.12.007. View

15.

Duley L . The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009; 33(3):130-7. DOI: 10.1053/j.semperi.2009.02.010. View

16.

Kjerulff L, Sanchez-Ramos L, Duffy D . Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol. 2011; 204(6):558.e1-6. DOI: 10.1016/j.ajog.2011.03.021. View

17.

Bhide P, Vartun A, Aune B, Flo K, Basnet P, Acharya G . Ovarian reserve in women with a previous history of severe pre-eclampsia. Arch Gynecol Obstet. 2016; 295(1):233-238. DOI: 10.1007/s00404-016-4193-8. View

18.

Oken E . Secular trends in birthweight. Nestle Nutr Inst Workshop Ser. 2013; 71:103-14. DOI: 10.1159/000342576. View

19.

van Disseldorp J, Eijkemans R, Fauser B, Broekmans F . Hypertensive pregnancy complications in poor and normal responders after in vitro fertilization. Fertil Steril. 2009; 93(2):652-7. DOI: 10.1016/j.fertnstert.2009.01.092. View

20.

Leader B, Baker V . Maximizing the clinical utility of antimüllerian hormone testing in women's health. Curr Opin Obstet Gynecol. 2014; 26(4):226-36. PMC: 4162336. DOI: 10.1097/GCO.0000000000000087. View